Meet with the men and women who are leading efforts to improve the quality and efficiency of our healthcare system. Talk with thought leaders who craft policy at the state and federal level. Engage with life sciences entrepreneurs who are discovering and commercializing products that can extend and improve our lives.
The Colloquium in Healthcare Leadership brings prominent leaders from public, private, and nonprofit healthcare organizations to campus for candid discussions. You will deepen your understanding of the major trends in healthcare as well as the challenges of being a leader in this space.
Thursday Evening Series - 6:30 PM, Beaumont Room, Sterling Hall of Medicine (2nd Floor), 333 Cedar Street
September 3, 2020 -- Introduction to Colloquium In Healthcare Leadership
Howard P. Forman, MD, MBA
Director, YSPH Health Care Management Program
Director, MD/MBA Program
Professor of Radiology & Public Health (Health Policy)
Professor in the Practice of Management
Professor of Economics (joint by courtesy)
Faculty Director, Executive MBA Program (Healthcare)
September 10, 2020
Jerome H. Kim, MD, Director General, The International Vaccine Institute
Jerome H. Kim
International Vaccine Institute
Jerome Kim, M.D., is the Director General of the International Vaccine Institute (IVI) and an international expert on the evaluation and development of vaccines. His depth and breadth of scientific experience span basic research through advanced clinical development. IVI’s oral cholera vaccine is used around the world to prevent this deadly diarrheal disease. IVI’s typhoid conjugate vaccine, tech-transferred to SK bioscience and PT Bio Farma, is completing Phase III testing. IVI is working on several different vaccines against COVID-19, including the clinical testing of Inovio’s DNA vaccine at Seoul National University Hospital and Genexine’s COVID-19 vaccine at Severance Hospital.
Dr. Kim was Principal Deputy and Chief, Laboratory of Molecular Virology and Pathogenesis ,in the U.S. Military HIV Research Program (MHRP) and also served as the Project Manager for the HIV Vaccines and Advanced Concepts Evaluation Project Management Offices, U.S. Army Medical Materiel Development Activity, Fort Detrick, MD. He led the Army's Phase III HIV vaccine trial (RV144) which was the first demonstration that an HIV vaccine could protect against infection, as well as subsequent studies that identified laboratory correlates and HIV sequence changes associated with vaccination.
Dr. Kim has authored over 250 publications and received the John Maher Award for Research Excellence from the Uniformed Services University of the Health Sciences in 2013 and the Department of the Army R&D Award for Technical Excellence (2013). Dr. Kim is also an Adjunct Professor of Medicine at the Uniformed Services University of the Health Sciences and at Yonsei University Graduate School of Public Health and a Fellow of the American College of Physicians and the Infectious Diseases Society of America.
He is a graduate of the University of Hawaii, with high honors in History and highest honors in Biology, and received his M.D. from Yale University School of Medicine.
September 17, 2020
Marna P. Borgstrom, MPH (’79), CEO and President, Yale New Haven Hospital and Yale New Haven Health Systems
Marna P. Borgstrom
Chief Executive Officer, Yale New Haven Health and Yale New Haven Hospital
Marna Borgstrom has served as the Chief Executive Officer of Yale New Haven Hospital and Yale New Haven Health since 2005. With revenues of $5.5B, Yale New Haven Health is the largest health system in the region and largest employer in Connecticut. Marna began her career at Yale-New Haven Hospital over 40 years ago and served in a variety of staff and operational roles prior to her current positions.
Marna chairs the boards of the Healthcare Institute and the Coalition to Protect America’s Healthcare and is the past chair of Vizient, a Dallas, Texas-based health care company. She serves on several other boards including the American Hospital Association, the Connecticut Hospital Association and New Haven Promise. She is also a director of Cryolife in Atlanta, GA.
Marna has been recognized for her commitment to community service and the health care field with numerous awards. She also holds five honorary doctorate degrees.
Marna received her undergraduate degree from Stanford University and was awarded a master’s of public health by the Yale University School of Epidemiology and Public Health. She is a lecturer at the Yale School of Epidemiology and Public Health, from which she received the Distinguished Alumni Award in 2018.
September 24, 2020
Bio to come.
October 1st, 2020
Kevin B. Churchwell, MD, President/COO, Executive VP of Health Affairs, Boston Children's Hospital
Kevin B. Churchwell, M.D.
President and Chief Operating Officer
Boston Children’s Hospital
Dr. Churchwell brings over 25 years of experience as a clinician, researcher, hospital executive and administrator, as well as a valuable perspective in designing and implementing patient treatments. He currently serves as president and chief operating officer at Boston Children’s Hospital where he has been since August 2013. He is also the Robert and Dan Smith Associate Professor of Anesthesia at Harvard Medical School. Previously, he served as chief executive officer of Nemours/Alfred I. DuPont Hospital for Children from 2010 to 2013 and as chief executive officer and executive director for the Monroe Carrell Jr. Children’s Hospital, part of the Vanderbilt University Medical Center, from 2007 to 2010. Dr. Churchwell has been a clinician and faculty member at Boston Children’s Hospital and Vanderbilt University Medical Center since 1993. Dr. Churchwell graduated with a B.S. in Biology from the Massachusetts Institute of Technology and received his M.D. from Vanderbilt Medical School.
October 8th, 2020
Eric Golding, MD, MBA ('05), Manager, Healthcare/Life Sciences Portfolio (Private Entity) (Former Vice President, Consonance Capital)
Eric M. Golding, M.D., M.B.A.
Dr. Golding is a physician by training with investment experience in both the private and public markets. He currently manages the healthcare/life sciences portfolio for a large family office.
Previously, he worked at Consonance Capital, a healthcare-only long/short public equity fund specializing in biopharmaceuticals, medical devices, diagnostics, and healthcare IT. Prior to joining Consonance, Dr. Golding worked in venture capital investing at F-Prime Capital Partners (formerly known as Fidelity Biosciences), a global venture capital firm specializing in biotechnology, pharmaceuticals, medical devices, diagnostics, and healthcare services/IT. While at F-Prime, Dr. Golding was a Board Observer for Iora Health, an IT-enabled healthcare services company focused on building and operating de novo primary care practices. He was also a Board Observer for Symbiomix Therapeutics, a company focused on developing therapeutics in the area of women’s health (acquired by Lupin).
Dr. Golding completed his training in Internal Medicine at Beth Israel Deaconess Medical Center, an affiliate of Harvard Medical School. He gained insight into the area of pharmaceutical regulation through an internship at the Food and Drug Administration in the Office of Regulatory Policy. He holds an MD from the Yale School of Medicine and an MBA from the Yale School of Management. He received a BA from the University of Pennsylvania, where he graduated summa cum laude.
October 29th, 2020
Sara Nayeem, MD, MBA ('06), Partner, NEA Venture Capital
Bio to come.
November 19, 2020
Carolyn M. Clancy, MD, Deputy Under Secretary for Health for Discovery, Education and Affiliate Networks (DEAN), U.S. Department of Veterans’ Affairs
Bio to come.
December 3rd, 2020
Pamela Sutton-Wallace, MPH, Senior Vice President & Regional Chief Operating Officer, New York Presbyterian Hospital
Bio to come.